Ignite Creation Date:
2025-12-24 @ 10:10 PM
Ignite Modification Date:
2026-05-17 @ 11:06 PM
Study NCT ID:
NCT04431635
Status:
TERMINATED
Last Update Posted:
2024-09-27
First Post:
2020-06-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
Sponsor:
University of Michigan Rogel Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Indolent Lymphoma | View |
Keywords: